Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 349 Oyster Point Boulevard SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://investors.23andme.com |
IR: | See website |
Key People | ||
Anne Wojcicki Chairman of the Board, President, Chief Executive Officer, Co-Founder | Joseph Selsavage Interim Chief Financial Officer, Chief Accounting Officer | Kathy L. Hibbs Chief Administrative Officer, Company Secretary |
Business Overview |
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients' lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates. |
Financial Overview |
For the nine months ended 31 December 2023, 23andMe Holding Co. revenues decreased 25% to $155.6M. Net loss increased 85% to $457.9M. Revenues reflect Research services segment decrease of 60% to $16.5M, Consumer services segment decrease of 15% to $111.7M, United Kingdom segment decrease of 56% to $20.7M, United States segment decrease of 15% to $124.7M. |
Employees: | 769 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4.06M as of Dec 31, 2023 |
Annual revenue (TTM): | $247.99M as of Dec 31, 2023 |
EBITDA (TTM): | -$296.84M as of Dec 31, 2023 |
Net annual income (TTM): | -$521.97M as of Dec 31, 2023 |
Free cash flow (TTM): | -$194.28M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 482,916,636 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |